[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 49 of about 49
1. Zhou FL, Zhang WG, Wei YC, Meng S, Bai GG, Wang BY, Yang HY, Tian W, Meng X, Zhang H, Chen SP: Involvement of oxidative stress in the relapse of acute myeloid leukemia. J Biol Chem; 2010 May 14;285(20):15010-5
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of oxidative stress in the relapse of acute myeloid leukemia.
  • The aims of the present study were to determine the level of oxidative stress and the salient factors leading to the relapse of acute myeloid leukemia (AML).
  • Oxidative stress-related parameters and the expressions of specific genes were monitored in 102 cases of AML during a pretreatment period from a primary status to a relapse status.
  • The activities of adenosine deaminase and xanthine oxidase were higher in the relapse condition, whereas those of glutathione peroxidase, monoamine oxidase, and superoxide dismutase, and the total antioxidant capacity (T-AOC) were lower in the primary condition and in controls.
  • Of particular note, levels of advanced oxidation protein products, malondialdehyde, and 8-hydroxydeoxyguanosine were also significantly higher in relapse patients.
  • Furthermore, real-time PCR with SYBR Green revealed that the expression levels of human thioredoxin (TRX) and indoleamine 2,3-dioxygenase were increased in relapse patients.
  • Linear regression showed that a low T-AOC and up-regulated TRX expression were the independent factors correlated with relapse.
  • A strong association between oxidative stress and the incidence of disease relapse was observed, which has potential prognosis implications.
  • These results indicate that oxidative stress is a crucial feature of AML and probably affects the development and relapse of AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / metabolism. Oxidative Stress

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Care Med. 2009 Jul;37(7):2155-9 [19487947.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1379-86 [16923572.001]
  • [Cites] Leuk Res. 2007 Mar;31(3):387-93 [16949154.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):792-801 [17234791.001]
  • [Cites] J Pharm Pharmacol. 2007 Mar;59(3):409-17 [17331345.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12288-93 [17640917.001]
  • [Cites] Immunol Lett. 2007 Aug 15;111(2):69-75 [17644189.001]
  • [Cites] Ann Surg Oncol. 2007 Sep;14(9):2616-20 [17564752.001]
  • [Cites] Diabetes. 2008 Apr;57(4):879-88 [18003754.001]
  • [Cites] Clin Biochem. 2008 May;41(7-8):511-8 [18313403.001]
  • [Cites] Leuk Res. 2008 Aug;32(8):1221-7 [18313749.001]
  • [Cites] Acta Physiol Hung. 2008 Jun;95(2):209-18 [18642760.001]
  • [Cites] Gen Physiol Biophys. 2008 Jun;27(2):71-84 [18645221.001]
  • [Cites] Antioxid Redox Signal. 2008 Oct;10(10):1813-48 [18593226.001]
  • [Cites] Leukemia. 2008 Sep;22(9):1685-91 [18580952.001]
  • [Cites] Pediatr Blood Cancer. 2008 Nov;51(5):613-5 [18623225.001]
  • [Cites] Biomed Environ Sci. 2008 Aug;21(4):286-9 [18837290.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Oct;295(4):C849-68 [18684987.001]
  • [Cites] Leukemia. 2008 Oct;22(10):1969-72 [18401418.001]
  • [Cites] Pediatr Blood Cancer. 2008 Dec;51(6):741-6 [18680148.001]
  • [Cites] Free Radic Biol Med. 2008 Sep 15;45(6):875-84 [18638547.001]
  • [Cites] Haematologica. 2008 Dec;93(12):1894-8 [19050070.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Feb;135(2):319-23 [18758816.001]
  • [Cites] Mol Nutr Food Res. 2009 Jan;53(1):87-103 [18979503.001]
  • [Cites] Leuk Res. 2009 Mar;33(3):490-4 [18639339.001]
  • [Cites] Zhongguo Dang Dai Er Ke Za Zhi. 2009 Feb;11(2):88-92 [19222940.001]
  • [Cites] Circ Res. 2009 Mar 27;104(6):750-7 [19179658.001]
  • [Cites] Oncologist. 2009 Mar;14(3):240-52 [19289488.001]
  • [Cites] J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009 Apr;27(2):120-39 [19412858.001]
  • [Cites] Cell Death Differ. 2009 Jun;16(6):847-57 [19247368.001]
  • [Cites] Leuk Res. 2009 Oct;33(10):1367-71 [19327827.001]
  • [Cites] Leuk Res. 2009 Oct;33(10):1297 [19560202.001]
  • [Cites] Nephron Clin Pract. 2009;112(4):c255-61 [19546585.001]
  • [Cites] Int J Neuropsychopharmacol. 2009 Sep;12(8):1089-96 [19272208.001]
  • [Cites] Environ Toxicol. 2009 Oct;24(5):446-52 [18979530.001]
  • [Cites] Cancer Biol Ther. 2009 Jul;8(14):1402-8 [19597340.001]
  • [Cites] Yonsei Med J. 2009 Oct 31;50(5):677-82 [19881972.001]
  • [Cites] J Mol Endocrinol. 2009 Dec;43(6):251-61 [19620238.001]
  • [Cites] Leuk Res. 2000 Jun;24(6):461-8 [10781678.001]
  • [Cites] Free Radic Biol Med. 2001 Jun 1;30(11):1286-92 [11368926.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 18;319(1):41-5 [15158439.001]
  • [Cites] J Clin Lab Anal. 1992;6(1):47-53 [1542083.001]
  • [Cites] Mol Cell Biochem. 2004 Nov;266(1-2):37-56 [15646026.001]
  • [Cites] Clin Chem Lab Med. 2005;43(3):294-7 [15843234.001]
  • [Cites] Drug Resist Updat. 2005 Oct;8(5):322-30 [16230045.001]
  • [Cites] Chem Biol Interact. 2006 Mar 10;160(1):1-40 [16430879.001]
  • [Cites] Perit Dial Int. 2006 Mar-Apr;26(2):207-12 [16623427.001]
  • [Cites] Toxicology. 2007 Jan 5;229(1-2):1-10 [17118505.001]
  • (PMID = 20233720.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase; EC 1.17.3.2 / Xanthine Oxidase; EC 1.4.3.4 / Monoamine Oxidase; EC 3.5.4.4 / Adenosine Deaminase
  • [Other-IDs] NLM/ PMC2865279
  •  go-up   go-down


2. Venizelos ID, Klonizakis I, Vlahaki E, Haralambidou S, Tatsiou Z, Ioannidou E: Skin relapse of acute myeloid leukemia associated with trisomy 8. Acta Dermatovenerol Alp Pannonica Adriat; 2007 Jun;16(2):77-80
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin relapse of acute myeloid leukemia associated with trisomy 8.
  • Acute myeloid leukemia (AML) is a morphologically diverse group of hematopoietic malignancies characterized by proliferation of immature cells that arise in the myeloid progenitor cells of the bone marrow.
  • [MeSH-major] Chromosomes, Human, Pair 8. Leukemia, Myeloid, Acute / pathology. Skin Neoplasms / pathology. Trisomy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17992463.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovenia
  •  go-up   go-down


3. Kim WI, Matise I, Diers MD, Largaespada DA: RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia. Blood; 2009 Jan 29;113(5):1086-96
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.
  • To study the oncogenic role of the NRAS oncogene (NRAS(G12V)) in the context of acute myeloid leukemia (AML), we used a Vav promoter-tetracycline transactivator (Vav-tTA)-driven repressible TRE-NRAS(G12V) transgene system in Mll-AF9 knock-in mice developing AML.
  • Conditional repression of NRAS(G12V) expression greatly reduced peripheral white blood cell (WBC) counts in leukemia recipient mice and induced apoptosis in the transplanted AML cells correlated with reduced Ras/Erk signaling.
  • We conclude that, in AML induced by an Mll-AF9 transgene, NRAS(G12V) expression contributes to acute leukemia maintenance by suppressing apoptosis and reducing differentiation of leukemia cells.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Genet Metab. 2006 Jul;88(3):216-24 [16678459.001]
  • [Cites] Int J Hematol. 2005 Jul;82(1):9-20 [16105754.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4392s-4395s [16857816.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Aug;3(8):448-57 [16894390.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2349-57 [16763213.001]
  • [Cites] Dev Cell. 2006 Dec;11(6):752-4 [17141149.001]
  • [Cites] Cell Cycle. 2006 Dec;5(24):2878-80 [17218790.001]
  • [Cites] Curr Opin Hematol. 2007 Mar;14(2):85-9 [17255784.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3291-310 [17496923.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5238-41 [17317860.001]
  • [Cites] Nat Rev Drug Discov. 2007 Jul;6(7):541-55 [17585331.001]
  • [Cites] Exp Hematol. 2007 Aug;35(8):1231-9 [17560009.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11657-67 [18089795.001]
  • [Cites] Leukemia. 2008 Jan;22(1):66-77 [17851551.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2329-38 [18056843.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2232-40 [16281072.001]
  • [Cites] Nat Genet. 2000 Jan;24(1):57-60 [10615128.001]
  • [Cites] Mol Membr Biol. 2000 Apr-Jun;17(2):65-73 [10989457.001]
  • [Cites] Cell Mol Life Sci. 2000 Dec;57(13-14):1950-63 [11215520.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5695-707 [11607819.001]
  • [Cites] Curr Opin Hematol. 2002 Jul;9(4):282-7 [12042701.001]
  • [Cites] Blood. 2002 Jul 1;100(1):238-45 [12070033.001]
  • [Cites] Science. 2002 Jul 5;297(5578):63-4 [12098689.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):433-43 [12124173.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:179-98 [12194988.001]
  • [Cites] Blood. 2002 Dec 1;100(12):4185-92 [12393454.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3229-35 [12515728.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8671-6 [14647461.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):597-602 [14699048.001]
  • [Cites] J Clin Invest. 2004 Feb;113(4):528-38 [14966562.001]
  • [Cites] Cell Cycle. 2004 May;3(5):536-7 [15020845.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(16):6993-7002 [15282300.001]
  • [Cites] Exp Hematol. 2004 Sep;32(9):852-60 [15345287.001]
  • [Cites] Cell. 1995 Feb 24;80(4):533-41 [7867061.001]
  • [Cites] Cell. 1996 Jun 14;85(6):853-61 [8681380.001]
  • [Cites] Environ Health Perspect. 1996 Dec;104 Suppl 6:1239-46 [9118899.001]
  • [Cites] Leukemia. 1998 May;12(5):792-800 [9593283.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11863-8 [9751756.001]
  • [Cites] Blood. 1999 Mar 15;93(6):2043-56 [10068678.001]
  • [Cites] EMBO J. 1999 Jul 1;18(13):3564-74 [10393173.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):535-8 [15607957.001]
  • [Cites] Semin Cancer Biol. 2005 Jun;15(3):175-88 [15826832.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1054-62 [15831708.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1368-76 [16761017.001]
  • (PMID = 18952898.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA084221; United States / NCI NIH HHS / CA / U01 CA84221
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mllt3 protein, mouse; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  • [Other-IDs] NLM/ PMC2635074
  •  go-up   go-down


Advertisement
4. von Falck C, Laenger F, Knapp WH, Galanski M: F-18 FDG PET/CT showing bilateral breast involvement in acute myeloid leukemia relapse. Clin Nucl Med; 2009 Oct;34(10):713-5
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 FDG PET/CT showing bilateral breast involvement in acute myeloid leukemia relapse.
  • Isolated extramedullary relapse with involvement of the breasts by acute myeloid leukemia (AML) after allogeneic stem cell transplantation is an uncommon event.
  • [MeSH-major] Breast / pathology. Breast / radionuclide imaging. Fluorodeoxyglucose F18. Leukemia, Myeloid, Acute / radiography. Leukemia, Myeloid, Acute / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19893411.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


5. Lancet JE, Karp JE: Novel postremission strategies in adults with acute myeloid leukemia. Curr Opin Hematol; 2009 Mar;16(2):105-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel postremission strategies in adults with acute myeloid leukemia.
  • PURPOSE OF REVIEW: Given the high rates of relapse in acute myeloid leukemia (AML), there is tremendous opportunity for the development of new therapeutic strategies in the postremission state.
  • The challenges to overcome therapeutic failure in the minimal residual disease status may relate to an incomplete understanding of the mechanisms and cell populations that are directly related to disease relapse as well as suboptimal ability to identify patients at highest risk for relapse.
  • RECENT FINDINGS: Being a heterogeneous disease, relapsed AML is unlikely to emanate from one predominant mechanism; instead, there are likely multiple biologic factors at play that allow for clinical relapse to occur.
  • These factors likely include multidrug resistance proteins, aberrant signal transduction pathways, survival of leukemia stem cells, microenvironmental interactions, and immune tolerance.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Sep 15;100(6):2132-7 [12200377.001]
  • [Cites] Br J Haematol. 2010 Aug;150(3):293-302 [20497178.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3142-9 [12468427.001]
  • [Cites] Leukemia. 2003 May;17(5):995-7 [12750723.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1202-10 [12663440.001]
  • [Cites] Nat Med. 2003 Sep;9(9):1158-65 [12897778.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1635-40 [14604977.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2817-24 [15087398.001]
  • [Cites] Haematologica. 2004 May;89(5):528-40 [15136215.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1438-40 [15175626.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1940-51 [15217827.001]
  • [Cites] Blood. 1992 May 1;79(9):2370-7 [1373973.001]
  • [Cites] N Engl J Med. 1994 Oct 6;331(14):896-903 [8078551.001]
  • [Cites] Exp Hematol. 1994 Dec;22(13):1252-60 [7957711.001]
  • [Cites] Br J Haematol. 1995 Feb;89(2):250-7 [7873374.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1416-34 [7888664.001]
  • [Cites] Leuk Res. 1996 Jul;20(7):591-600 [8795693.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2450-7 [8839835.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1405-12 [9028964.001]
  • [Cites] Blood. 1997 May 1;89(9):3104-12 [9129012.001]
  • [Cites] Blood. 1997 May 1;89(9):3323-9 [9129038.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2465-70 [9310499.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1713-24 [12200686.001]
  • [Cites] Leukemia. 2000 Apr;14(4):602-11 [10764145.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3948-52 [11090082.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(3):893-901 [11154276.001]
  • [Cites] Exp Hematol. 2001 Apr;29(4):448-57 [11301185.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):713-26 [11380463.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2301-7 [11588023.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3212-20 [11719356.001]
  • [Cites] Exp Hematol. 2001 Dec;29(12):1439-47 [11750103.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2429-40 [12011120.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1224-32 [12149202.001]
  • [Cites] Cell. 1997 Oct 17;91(2):231-41 [9346240.001]
  • [Cites] Curr Opin Cell Biol. 1998 Apr;10(2):262-7 [9561851.001]
  • [Cites] Blood. 1998 Aug 1;92(3):784-9 [9680345.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1375-82 [9737685.001]
  • [Cites] Blood. 1999 Feb 1;93(3):787-95 [9920827.001]
  • [Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4131-43 [10361110.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1086-99 [10419902.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3078-85 [15284114.001]
  • [Cites] Leukemia. 2005 Apr;19(4):586-94 [15703783.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4163-9 [15687234.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1867-74 [15890685.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1090-8 [16435386.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1794-803 [16532500.001]
  • [Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]
  • [Cites] Haematologica. 2006 Jun;91(6):833-6 [16769587.001]
  • [Cites] Blood. 2006 Jul 1;108(1):88-96 [16556892.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1783-9 [16838027.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4427-35 [17804695.001]
  • [Cites] Leukemia. 2008 Jan;22(1):147-60 [17928881.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3077-82 [18483374.001]
  • [Cites] Blood. 2008 Aug 15;112(4):990-8 [18426988.001]
  • [Cites] Blood. 2009 Jun 11;113(24):6215-24 [18955566.001]
  • [CommentIn] Curr Opin Hematol. 2009 Mar;16(2):63 [19468265.001]
  • (PMID = 19468272.001).
  • [ISSN] 1531-7048
  • [Journal-full-title] Current opinion in hematology
  • [ISO-abbreviation] Curr. Opin. Hematol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000052; United States / NCRR NIH HHS / RR / RR000052-466559; United States / NCRR NIH HHS / RR / M01 RR000052-466559
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 64
  • [Other-IDs] NLM/ NIHMS187903; NLM/ PMC2861990
  •  go-up   go-down


6. Jacobi A, Thieme S, Lehmann R, Ugarte F, Malech HL, Koch S, Thiede C, Müller K, Bornhäuser M, Ryser M, Brenner S: Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts. Exp Hematol; 2010 Mar;38(3):180-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Internal tandem duplication (ITD) mutations of the FLT3 receptor are associated with a high incidence of relapse in acute myeloid leukemia (AML).

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20035824.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / Z01 AI000988; United States / Intramural NIH HHS / / Z01 AI000988-02; United States / Intramural NIH HHS / / ZIA AI000988-03; United States / Intramural NIH HHS / / ZIA AI000988-04
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CXCR4 protein, human; 0 / Heterocyclic Compounds; 0 / Receptors, CXCR4; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / STAT5 Transcription Factor; 0 / STAT5A protein, human; 0 / Tumor Suppressor Proteins; 155148-31-5 / JM 3100; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  • [Other-IDs] NLM/ NIHMS762780; NLM/ PMC4777334
  •  go-up   go-down


7. Ragusa M, Avola G, Angelica R, Barbagallo D, Guglielmino MR, Duro LR, Majorana A, Statello L, Salito L, Consoli C, Camuglia MG, Di Pietro C, Milone G, Purrello M: Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy. BMC Cancer; 2010;10:377
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy.
  • BACKGROUND: According to the different sensitivity of their bone marrow CD34+ cells to in vitro treatment with Etoposide or Mafosfamide, Acute Myeloid Leukaemia (AML) patients in apparent complete remission (CR) after chemotherapy induction may be classified into three groups: (i) normally responsive;.
  • This inversely correlates with in vivo CD34+ mobilization and, interestingly, also with the prognosis of the disease: patients showing a good mobilizing activity are resistant to chemotherapy and subject to significantly higher rates of Minimal Residual Disease (MRD) and relapse than the others.
  • METHODS: To investigate the molecular bases of the differential chemosensitivity of bone marrow hematopoietic stem cells (HSC) in CR AML patients, and the relationship between chemosensitivity, mobilizing activity and relapse rates, we analyzed their AM expression profile by performing Real Time RT-PCR of 84 AM genes in CD34+ pools from the two extreme classes of patients (i.e., chemoresistant and highly chemosensitive), and compared them with normal controls.
  • We propose that their dysregulation (either due to inborn or de novo genomic mutations selected by treatment) could cause a relapse in apparent CR AML patients.
  • Based on this, AM profiling before chemotherapy and transplantation could identify patients with a predisposing genotype to MRD and relapse: accordingly, they should undergo a different, specifically tailored, therapeutic regimen and should be carefully checked during the post-treatment period.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis. Biomarkers, Tumor / genetics. Bone Marrow Cells / metabolism. Drug Resistance, Neoplasm / genetics. Gene Expression Profiling. Leukemia, Myeloid, Acute / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1993 Jul 1;82(1):15-21 [8324219.001]
  • [Cites] Int J Biochem Cell Biol. 2009 Dec;41(12):2372-5 [19699815.001]
  • [Cites] Oncogene. 2006 Feb 9;25(6):838-48 [16247474.001]
  • [Cites] Mayo Clin Proc. 2006 Feb;81(2):247-60 [16471082.001]
  • [Cites] Toxicol Sci. 2006 Aug;92(2):587-95 [16675512.001]
  • [Cites] CA Cancer J Clin. 1996 May-Jun;46(3):165-84 [8646546.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2048-59 [9058727.001]
  • [Cites] Leukemia. 1998 Mar;12(3):382-9 [9529133.001]
  • [Cites] Leuk Res. 1998 Jun;22(6):557-60 [9678722.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] J Leukoc Biol. 2004 Nov;76(5):1047-56 [15328334.001]
  • [Cites] Cell Death Differ. 2005 Jun;12(6):682-6 [15861191.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4770-4 [16000573.001]
  • [Cites] Med Princ Pract. 2005;14 Suppl 1:35-48 [16103712.001]
  • [Cites] Br J Haematol. 2000 Jun;109(3):611-5 [10886211.001]
  • [Cites] Curr Opin Oncol. 2001 Jan;13(1):21-6 [11148681.001]
  • [Cites] Curr Opin Oncol. 2001 Nov;13(6):463-9 [11673686.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3284-94 [12032770.001]
  • [Cites] Leukemia. 2003 Jan;17(1):60-7 [12529661.001]
  • [Cites] Leukemia. 2003 Jan;17(1):68-75 [12529662.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):434-41 [12580957.001]
  • [Cites] Biotechniques. 2003 Feb;34(2):374-8 [12613259.001]
  • [Cites] Genome Res. 2003 Nov;13(11):2498-504 [14597658.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3657-61 [14666661.001]
  • [Cites] Leukemia. 2004 Jan;18(1):1-10 [14574330.001]
  • [Cites] Leukemia. 2004 Feb;18(2):358-60 [14628070.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):26915-21 [15078892.001]
  • [Cites] J Clin Immunol. 2004 Sep;24(5):553-60 [15359114.001]
  • [Cites] Blood Rev. 2006 Nov;20(6):333-42 [16920238.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:169-77 [17124057.001]
  • [Cites] Lancet. 2006 Nov 25;368(9550):1894-907 [17126723.001]
  • [Cites] Curr Pharm Des. 2006;12(34):4411-25 [17168751.001]
  • [Cites] Acta Haematol. 2007;117(1):8-15 [17095854.001]
  • [Cites] Cancer Biol Ther. 2007 Feb;6(2):209-17 [17224646.001]
  • [Cites] Exp Hematol. 2007 Jun;35(6):957-66 [17533050.001]
  • [Cites] Bioinformatics. 2007 Sep 15;23(18):2495-7 [17644818.001]
  • [Cites] Mol Syst Biol. 2007;3:152 [18091723.001]
  • [Cites] Bioinformatics. 2008 Jan 15;24(2):282-4 [18006545.001]
  • [Cites] Cell Biol Int. 2008 Mar;32(3):329-36 [18243739.001]
  • [Cites] Blood. 2008 Apr 15;111(8):3923-30 [18398055.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2519-26 [18451212.001]
  • [Cites] Pharmacology. 2008;81(4):275-300 [18259091.001]
  • [Cites] Br J Haematol. 2008 Jul;142(1):74-8 [18422993.001]
  • [Cites] Leuk Res. 2008 Nov;32(11):1684-97 [18339423.001]
  • [Cites] Semin Oncol. 2008 Aug;35(4):365-77 [18692687.001]
  • [Cites] Exp Hematol. 2008 Dec;36(12):1660-72 [18838202.001]
  • [Cites] Nat Rev Cancer. 2009 Sep;9(9):665-74 [19693095.001]
  • [Cites] Physiology (Bethesda). 2005 Oct;20:349-56 [16174874.001]
  • (PMID = 20642818.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2914706
  •  go-up   go-down


8. Martner A, Thorén FB, Aurelius J, Söderholm J, Brune M, Hellstrand K: Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia. Expert Rev Hematol; 2010 Aug;3(4):381-91
Hazardous Substances Data Bank. HISTAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.
  • Most patients with acute myeloid leukemia (AML) achieve complete remission (CR) after induction chemotherapy.
  • HDC reduces myeloid cell-derived suppression of anti-leukemic lymphocytes, and aims to unravel a therapeutic benefit of IL-2 in AML by improving natural killer and T-cell activation.
  • A randomized Phase III trial with 320 AML patients in CR demonstrated a significant reduction of relapse risk after immunotherapy with HDC plus low-dose IL-2 in the post-consolidation phase.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Histamine / therapeutic use. Immunotherapy. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21083028.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2; 820484N8I3 / Histamine
  •  go-up   go-down


9. Doubek M, Palasek I, Pospisil Z, Borsky M, Klabusay M, Brychtova Y, Jurcek T, Jeziskova I, Krejci M, Dvorakova D, Mayer J: Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression. Exp Hematol; 2009 Jun;37(6):659-72
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
  • OBJECTIVE: Our objective was to determine the value of frequent minimal residual disease (MRD) monitoring in acute myeloid leukemia (AML) as a robust marker of impending relapse, and whether treatment benefits patients during the MRD-positive phase of their disease.
  • Moreover, no universal value of the WT1 expression could unequivocally discriminate between remission and relapse.
  • Considering relapsed patients, duration from molecular to hematological relapse was 8 to 79 days (median: 25.5 days).
  • CONCLUSIONS: Frequent quantitative monitoring of fusion transcripts is useful for reliably predicting hematological relapse in AML patients.
  • Treatment for molecular relapse of AML can be successful.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Neoplasm Proteins / analysis. Neoplasm, Residual / diagnosis. Translocation, Genetic. WT1 Proteins / analysis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Case-Control Studies. Core Binding Factor Alpha 2 Subunit / analysis. Core Binding Factor beta Subunit / analysis. Female. Humans. Male. Middle Aged. Myeloid-Lymphoid Leukemia Protein / analysis. Recurrence. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19463768.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CBFB protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Core Binding Factor beta Subunit; 0 / Neoplasm Proteins; 0 / RUNX1 protein, human; 0 / WT1 Proteins; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  •  go-up   go-down


10. Kiratli H, Demiroğlu H, Emeç S: Ocular relapse in acute myeloid leukemia (M4) with normal bone marrow. Int Ophthalmol; 2009 Aug;29(4):243-5
MedlinePlus Health Information. consumer health - Eye Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular relapse in acute myeloid leukemia (M4) with normal bone marrow.
  • A patient with the rare occurrence of ocular relapse of acute myeloid leukemia (AML) M4 while the bone marrow was normal is reported in this paper.
  • The ocular relapse involved the subconjunctival space and anterior chamber of the left eye and, presumably, the left lacrimal gland.
  • Although exceedingly rare, ocular extramedullary relapse in AML M4 heralds bone marrow recurrence and, despite intensive chemotherapy, the prognosis is dismal.
  • [MeSH-major] Bone Marrow / pathology. Eye / pathology. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / pathology. Sarcoma, Myeloid / etiology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Feb 1;85(3):608-15 [10091734.001]
  • [Cites] N Z Med J. 1996 Jun 28;109(1024):242 [8769042.001]
  • [Cites] Hematol Oncol. 1999 Jun;17(2):45-52 [10521868.001]
  • [Cites] Bone Marrow Transplant. 1996 May;17(5):801-8 [8733701.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1800-16 [7602369.001]
  • [Cites] Am J Ophthalmol. 1999 Mar;127(3):361-3 [10088758.001]
  • (PMID = 18338107.001).
  • [ISSN] 1573-2630
  • [Journal-full-title] International ophthalmology
  • [ISO-abbreviation] Int Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Schumann M, Kiewe P, Hartlieb S, Neumann M, Schilling A, Koch HC, Thiel E, Korfel A: Diffuse leukoencephalopathy and brain edema: unusual presentations of CNS relapse of acute myeloid leukemia. J Neuroimaging; 2010 Apr;20(2):198-200
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse leukoencephalopathy and brain edema: unusual presentations of CNS relapse of acute myeloid leukemia.
  • An isolated CNS relapse is rarely seen in acute myeloid leukemia.
  • With the one-year-old history of an initially successfully treated FAB-M0 acute myeloid leukemia (AML) in mind, a lumbar puncture was carried out that showed a vast number of myeloid blasts in the morphologic analysis of the cerebrospinal fluid.
  • In conjunction with normal findings in the peripheral blood-count with differential and the bone marrow examination a diagnosis of an isolated CNS relapse of the AML was made.
  • [MeSH-major] Brain Edema / diagnosis. Brain Edema / etiology. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / diagnosis. Leukoencephalopathies / diagnosis. Leukoencephalopathies / etiology. Magnetic Resonance Imaging


12. Hudecek M, Bartsch K, Jäkel N, Heyn S, Pfannes R, Al-Ali HK, Cross M, Pönisch W, Gerecke U, Edelmann J, Ittel T, Niederwieser D: Spontaneous remission of acute myeloid leukemia relapse after hematopoietic cell transplantation in a high-risk patient with 11q23/MLL abnormality. Acta Haematol; 2008;119(2):111-4
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of acute myeloid leukemia relapse after hematopoietic cell transplantation in a high-risk patient with 11q23/MLL abnormality.
  • A 35-year-old female patient was diagnosed with acute myeloid leukemia with multiple genetic aberrations [48 XX, del(3)(q21), +6, t(11;15)(q23;q15), +21] including an 11q23/MLL abnormality.
  • In the absence of any disease-specific treatment, the leukemic blasts cleared from the bone marrow within 6 days after diagnosis of relapse and peripheral blood counts returned to normal.
  • This is the first report of spontaneous remission in a patient with initially a multiaberrant leukemic cell clone and a proven 11q23/MLL abnormality at relapse after HCT.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 11. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / pathology. Myeloid-Lymphoid Leukemia Protein / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel
  • (PMID = 18367831.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


13. Ruggeri L, Capanni M, Mancusi A, Perruccio K, Burchielli E, Martelli MF, Velardi A: Natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Int J Hematol; 2005 Jan;81(1):13-7
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After haploidentical hematopoietic transplantation, NK cell-mediated donor-versus-recipient alloresponses reduce the risk of relapse in acute myeloid leukemia patients while improving engraftment and protecting against graft-versus-host disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 1997 Dec;7(6):753-63 [9430221.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1935-47 [12200350.001]
  • [Cites] Blood. 2003 Aug 1;102(3):814-9 [12689936.001]
  • [Cites] J Exp Med. 1992 Oct 1;176(4):963-71 [1328466.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12000-4 [8265660.001]
  • [Cites] Trends Immunol. 2002 Sep;23(9):438-44 [12200065.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):323-6 [14531915.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2860-1; author reply 2862 [15033884.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):7983-5 [1518825.001]
  • [Cites] J Exp Med. 1988 Dec 1;168(6):2403-8 [2974067.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1268-73 [7489407.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3825-7 [12393440.001]
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Dec;87(24):9794-7 [1979875.001]
  • [Cites] Blood. 1999 Jul 1;94(1):333-9 [10381530.001]
  • [Cites] N Engl J Med. 1998 Oct 22;339(17):1186-93 [9780338.001]
  • [Cites] Eur J Immunol. 1994 Apr;24(4):1003-6 [8149950.001]
  • [Cites] J Immunol. 2003 Dec 15;171(12):6640-9 [14662867.001]
  • [Cites] Science. 1993 May 21;260(5111):1121-4 [8493555.001]
  • [Cites] Immunol Today. 1995 Sep;16(9):437-40 [7546208.001]
  • [Cites] Nature. 1986 Feb 20-26;319(6055):675-8 [3951539.001]
  • [Cites] Science. 1999 Jul 16;285(5426):412-5 [10411505.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3948-55 [7524753.001]
  • [Cites] J Exp Med. 1992 Mar 1;175(3):709-18 [1371301.001]
  • [Cites] Blood. 2003 May 1;101(9):3730-40 [12511415.001]
  • (PMID = 15717682.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 PO1 CA100265-01A1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Isoantigens
  • [Number-of-references] 32
  •  go-up   go-down


14. Shereck E, Satwani P, Morris E, Cairo MS: Human natural killer cells in health and disease. Pediatr Blood Cancer; 2007 Oct 15;49(5):615-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In haploidentical stem cell transplantation with purified stem cells, NK cell alloreactivity (killer immunoglobulin-like receptor [KIR] mismatch) has been demonstrated to reduce the risk of relapse in acute myeloid leukemia.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17265453.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 82
  •  go-up   go-down


15. Unal S, Cakir M, Kuşkonmaz B, Cetin M, Tuncer AM: Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia. Turk J Pediatr; 2009 Jan-Feb;51(1):69-71
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia.
  • There are few therapeutic options in relapsed or refractory acute myeloid leukemia patients.
  • Herein, we present a 15-year-old acute myeloid leukemia patient who was resistant at relapse and could achieve remission with gemtuzumab ozogamicin at a total dose of 9 mg/m2, divided into three doses and delivered to hematopoietic stem-cell transplantation; however, the patient relapsed in a short time without application of transplantation.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378895.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / gemtuzumab
  •  go-up   go-down


16. Amalraj P, Syamlal S: Unusual case of paraplegia. Ann Indian Acad Neurol; 2009 Jul;12(3):188-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Paraplegia due to a spinal cord epidural mass is an extremely rare presentation of undiagnosed leukemia.
  • We are reporting a case of 14-year-old girl, who presented with paraplegia due to thoracic epidural mass, as the initial presenting manifestation of acute myeloid leukemia.
  • Granulocytic sarcoma or chloroma should be considered in the differential diagnosis of an epidural mass in patients with or with out leukemia granulocytic sarcoma, which are rare extramedullary tumor-like proliferation of myelogenous precursor cells that may de novo precede acute leukemia or coincide with the first manifestation or relapse of acute myeloid leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Hematol. 2006 Mar;85(3):196-7 [16389563.001]
  • [Cites] J Assoc Physicians India. 2005 Sep;53:828 [16334633.001]
  • [Cites] Skeletal Radiol. 1998 Feb;27(2):112-4 [9526779.001]
  • [Cites] Neurosurgery. 2000 Jan;46(1):78-83; discussion 83-4 [10626938.001]
  • [Cites] Leuk Lymphoma. 2003 Oct;44(10):1753-60 [14692530.001]
  • [Cites] Pathology. 2001 Aug;33(3):386-9 [11523946.001]
  • [Cites] Am J Hematol. 2004 May;76(1):95-6 [15114610.001]
  • (PMID = 20174502.001).
  • [ISSN] 1998-3549
  • [Journal-full-title] Annals of Indian Academy of Neurology
  • [ISO-abbreviation] Ann Indian Acad Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2824938
  • [Keywords] NOTNLM ; Acute myeloid leukemia / chloroma / granulocytic sarcoma
  •  go-up   go-down


17. Guo H, Qian X: Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects. Onkologie; 2010;33(7):389-95
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NK cell alloreactivity has been demonstrated to enhance control of acute myeloid leukemia relapse and greatly reduce the risk of graft-versus-host disease in HLA haplotype-mismatched hematopoietic transplantation, and has been explored as a tool for adoptive immunotherapy for cancer patients.
  • [MeSH-major] Immunotherapy, Adoptive / methods. Immunotherapy, Adoptive / trends. Killer Cells, Natural / immunology. Killer Cells, Natural / transplantation. Leukemia / immunology. Leukemia / therapy. Neoplasms / immunology. Neoplasms / therapy
  • [MeSH-minor] Forecasting. Graft vs Host Reaction / immunology. Graft vs Leukemia Effect / immunology. HLA Antigens. Haplotypes. Histocompatibility Testing. Humans. Receptors, Natural Killer Cell / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20631487.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / Receptors, Natural Killer Cell
  •  go-up   go-down


18. Ruggeri L, Mancusi A, Perruccio K, Burchielli E, Martelli MF, Velardi A: Natural killer cell alloreactivity for leukemia therapy. J Immunother; 2005 May-Jun;28(3):175-82
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural killer cell alloreactivity for leukemia therapy.
  • Transplantation from NK alloreactive haploidentical donors controls acute myeloid leukemia relapse and improves engraftment without causing graft-versus-host disease.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Killer Cells, Natural / immunology. Leukemia / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15838373.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P01 CA100265-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-A Antigens
  • [Number-of-references] 74
  •  go-up   go-down


19. Dorantes-Acosta E, Arreguin-Gonzalez F, Rodriguez-Osorio CA, Sadowinski S, Pelayo R, Medina-Sanson A: Acute myelogenous leukemia switch lineage upon relapse to acute lymphoblastic leukemia: a case report. Cases J; 2009;2:154

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia switch lineage upon relapse to acute lymphoblastic leukemia: a case report.
  • Acute leukemia, the most common form of cancer in children, accounts for approximately 30% of all childhood malignancies, with acute lymphoblastic leukemia being five times more frequent than acute myeloid leukemia.
  • Lineage switch is the term that has been used to describe the phenomenon of acute leukemias that meet the standard French-American-British system criteria for a particular lineage (either lymphoid or myeloid) upon initial diagnosis, but meet the criteria for the opposite lineage at relapse.
  • Many reports have documented conversions of acute lymphoblastic leukemia to acute myeloid leukemia.
  • Here, we report the case of a 4-year-old child with acute myeloid leukemia, which upon relapse switched to acute lymphoblastic leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ther Clin Risk Manag. 2008 Apr;4(2):327-36 [18728851.001]
  • [Cites] Blood. 2002 Jan 15;99(2):409-26 [11781220.001]
  • [Cites] Cell Cycle. 2008 May 15;7(10):1315-20 [18418081.001]
  • [Cites] Nat Rev Immunol. 2008 Feb;8(2):95-106 [18204470.001]
  • [Cites] Trends Mol Med. 2007 Nov;13(11):470-81 [17981087.001]
  • [Cites] Nat Immunol. 2007 May;8(5):463-70 [17440452.001]
  • [Cites] Leukemia. 2006 Nov;20(11):1963-6 [17008890.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Hematol Oncol Clin North Am. 1990 Aug;4(4):767-94 [2228896.001]
  • [Cites] Blood. 1989 Nov 1;74(6):2088-95 [2553159.001]
  • [Cites] Clin Haematol. 1986 Aug;15(3):811-27 [3536242.001]
  • [Cites] Blood. 1984 Sep;64(3):701-6 [6590097.001]
  • [Cites] Cancer. 1983 Nov 1;52(9):1712-9 [6352006.001]
  • [Cites] J Leukoc Biol. 2004 Jun;75(6):973-81 [14982952.001]
  • [Cites] Leukemia. 2008 Aug;22(8):1503-18 [18548105.001]
  • (PMID = 19946525.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2783110
  •  go-up   go-down


20. Shih LY, Liang DC, Huang CF, Wu JH, Lin TL, Wang PN, Dunn P, Kuo MC, Tang TC: AML patients with CEBPalpha mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: a comparative analysis on paired diagnosis and relapse samples. Leukemia; 2006 Apr;20(4):604-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AML patients with CEBPalpha mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: a comparative analysis on paired diagnosis and relapse samples.
  • The roles of CEBPalpha mutations and its cooperating mutations in the relapse of acute myeloid leukemia (AML) are not clear.
  • CEBPalpha mutations were analyzed on 149 patients with de novo AML at both diagnosis and relapse.
  • Twenty patients relapsed with identical mutant patterns, two lost CEBPalpha mutations and none acquired the mutations at relapse.
  • Cloning analysis showed that the N-terminal and C-terminal mutations occurred on separate cloned alleles and also on the same alleles in most of the diagnosis and relapse samples.
  • Our study showed that 91% of de novo AML harboring CEBPalpha mutations at diagnosis retained the identical mutant patterns but frequently changed in the allelic distribution at relapse.
  • [MeSH-major] CCAAT-Enhancer-Binding Protein-alpha / genetics. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics. Mutation

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16453003.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Protein-alpha; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


21. Specchia G, Pastore D, Carluccio P, Spinosa G, Giannoccaro M, Rizzi R, Mestice A, Liso V: Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience. Ann Hematol; 2007 Jun;86(6):425-8
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience.
  • We analyzed the safety and efficacy of gemtuzumab ozogamicin (GO) combined with cytarabine and mitoxantrone in the treatment of 21 patients with acute myeloid leukemia (11 refractory and 10 in second relapse).
  • In our experience, the addition of GO to mitoxantrone and cytarabine is feasible in refractory or second relapse acute myeloid leukemia patients but yields a low response rate when used as a third-line treatment.
  • [MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Antibodies, Monoclonal, Humanized. Cytarabine / administration & dosage. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Palliative Care / methods. Remission Induction. Salvage Therapy / methods. Survival Analysis

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364181.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / gemtuzumab; 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


22. McCormick SR, McCormick MJ, Grutkoski PS, Ducker GS, Banerji N, Higgins RR, Mendiola JR, Reinartz JJ: FLT3 mutations at diagnosis and relapse in acute myeloid leukemia: cytogenetic and pathologic correlations, including cuplike blast morphology. Arch Pathol Lab Med; 2010 Aug;134(8):1143-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLT3 mutations at diagnosis and relapse in acute myeloid leukemia: cytogenetic and pathologic correlations, including cuplike blast morphology.
  • CONTEXT: Acquired mutations in the fms-like tyrosine kinase 3 gene (FLT3) adversely impact relapse risk after chemotherapy in patients with acute myeloid leukemia (AML).
  • The FLT3 mutation status may differ at diagnosis and relapse, suggesting a potential role in chemoresistance, yet few reports have addressed the cytogenetic and pathologic correlates of FLT3 mutations in relapsed AML.
  • OBJECTIVES: To determine FLT3 mutations at diagnosis and relapse in a cohort of adult patients with chemoresistant AML and to correlate mutation status with multiple variables.
  • DESIGN: We retrospectively determined FLT3 internal tandem duplication (FLT3/ITD) and FLT3 tyrosine kinase domain mutations in 50 diagnosis/relapse pairs.
  • RESULTS: In 11 of 50 patients (22%) the FLT3 mutation status differed at relapse and diagnosis, with a trend toward gain of FLT3/ITD (n = 7) and loss of FLT3 tyrosine kinase domain (n = 5) mutations.
  • FLT3-mutated AMLs correlated with the World Health Organization 2008 subtype, AML, not otherwise specified, hyperproliferative features at diagnosis and relapse, and cytogenetic evolution.
  • Four of 7 patients with relapse-only FLT3/ITD mutations exhibited cuplike blasts at relapse after being noncuplike at diagnosis.
  • CONCLUSIONS: In addition to well-known correlates in pretreatment specimens, FLT3 mutation status has pathologic and cytogenetic significance at relapse.
  • A shift to cuplike blast morphology at relapse may herald emergence of a previously undetected FLT3/ITD mutation.
  • [MeSH-major] Gene Duplication. Leukemia, Myeloid, Acute / genetics. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20670134.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


23. Grier DD, Eskew A, White T, McLean TW: An unusual case of acute myeloid leukemia: late isolated testicular relapse followed by isolated central nervous system relapse. Pediatr Blood Cancer; 2010 Dec 1;55(6):1231-3
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of acute myeloid leukemia: late isolated testicular relapse followed by isolated central nervous system relapse.
  • Testicular relapse of acute myeloid leukemia without bone marrow involvement is a rare event.
  • We describe a case of an 18-year-old male who had an isolated testicular relapse 86 months (7.2 years) from original diagnosis.
  • Fluorescence in situ hybridization and immunohistochemistry were used to establish the diagnosis of a relapse rather than a new leukemic process.
  • This patient had a 7.2-year period between original diagnosis and the testicular relapse of acute myeloid leukemia.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Leukemia, Myeloid, Acute / surgery. Neoplasm Recurrence, Local / diagnosis. Testicular Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20589624.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; FTK8U1GZNX / Thioguanine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


24. Owonikoko T, Agha M, Balassanian R, Smith R, Raptis A: Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. Nat Clin Pract Oncol; 2007 Aug;4(8):491-5
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant.
  • BACKGROUND: A 19-year-old male with primary refractory acute myeloid leukemia received salvage therapy with mitoxantrone and cytarabine combination.
  • Ten months following repeat transplant, the patient presented with an increasing number of extramedullary sites of biopsy-proven disease relapse (i.e. cranial and peripheral nerves, tongue, abdominal wall and chest wall).
  • DIAGNOSIS: Isolated extramedullary relapse of acute myeloid leukemia after stem-cell transplant.
  • MANAGEMENT: Primary leukemia treatment with idarubicin, cytarabine, etoposide, dexamethasone, tioguanine on protocol and salvage therapy with mitoxantrone and cytarabine combination for primary refractory disease.
  • A matched-unrelated-donor stem-cell transplant for consolidation and donor-lymphocyte infusions were performed, followed by repeat unrelated-donor transplant for leukemia relapse in the marrow, radiation therapy and gemtuzumab ozogamicin for multiple sites of extramedullary leukemia relapse.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation / adverse effects. Neoplasm Recurrence, Local / drug therapy. Sarcoma, Myeloid / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657254.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / gemtuzumab
  •  go-up   go-down


25. Huisman C, de Weger RA, de Vries L, Tilanus MG, Verdonck LF: Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transplant; 2007 Mar;39(5):285-91
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia.
  • The role of chimerism analysis as a prognostic indicator of relapse after hematopoietic stem cell transplantation (SCT) is controversial.
  • We monitored chimerism status by short tandem repeat-based polymerase chain reaction (PCR) in T- and non-T-cell subsets and retrospectively evaluated clinical outcome in 96 patients with acute myeloid leukemia after myeloablative (MA) or reduced-intensity conditioning SCT.
  • Forty-three out of 96 patients experienced relapse.
  • The last chimerism evaluation before relapse revealed increasing MC in only eight patients.
  • In samples taken between 1 and 6 months post SCT, CC/decreasing MC was significantly related with a lower risk of relapse (31 versus 83%, P<0.000) and mortality (38 versus 83%, P<0.000) than with MC/increasing MC.
  • However, the development of relapse was very rapid.
  • Only very frequent monitoring of chimerism status by highly sensitive methods might identify impending relapse and allow early immunological intervention.
  • [MeSH-major] Bone Marrow Transplantation. Chimerism. Leukemia, Myeloid, Acute / genetics. Microsatellite Repeats / genetics. Polymerase Chain Reaction. Transplantation Chimera / genetics


26. Velardi A: Role of KIRs and KIR ligands in hematopoietic transplantation. Curr Opin Immunol; 2008 Oct;20(5):581-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review focuses on recent research demonstrating the role alloreactive natural killer (NK) cells play in adoptive immunotherapy of leukemia in allogeneic hematopoietic transplantation.
  • However, up to one half of patients relapse and do not make it to transplant during the time required for the donor search, completion of donor HLA typing, bone marrow harvest, and shipment.
  • It improves outcomes of HLA haplotype-mismatched ('haploidentical') transplants by controlling acute myeloid leukemia relapse without causing graft-versus-host disease.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18675345.001).
  • [ISSN] 0952-7915
  • [Journal-full-title] Current opinion in immunology
  • [ISO-abbreviation] Curr. Opin. Immunol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P01 CA100265
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / Ligands; 0 / Receptors, KIR
  • [Number-of-references] 57
  •  go-up   go-down


27. Usmani SZ, Shahid Z, Saleh H, Nasser KA: Myeloid sarcoma presenting with acute renal failure and bilateral ureteral obstruction: a case report and review of the literature. Am J Med Sci; 2007 Aug;334(2):136-8
Genetic Alliance. consumer health - Myeloid sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid sarcoma presenting with acute renal failure and bilateral ureteral obstruction: a case report and review of the literature.
  • Myeloid sarcoma (MS) is a very rare disease that either presents with acute myeloid leukemia or as relapse of acute myeloid leukemia.
  • We present an unusual case of MS presenting with acute renal failure (ARF) and bilateral ureteral obstruction.
  • Pelvic mass biopsy showed fibroadipose tissue with diffuse neoplastic cell infiltration and immunostaining was positive for leukocyte common antigen (LCA) and myeloperoxidase consistent with myeloid sarcoma.
  • To our knowledge, this case is the first description of myeloid sarcoma presenting with ARF and bilateral ureteral obstruction not originating from urogenital system.
  • [MeSH-major] Acute Kidney Injury / etiology. Sarcoma, Myeloid / diagnosis. Ureteral Obstruction / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17700206.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


28. Thomas-Kaskel AK, Portugal TG, Herchenbach D, Houet L, Veelken H, Finke J: Allogeneic HLA-matched donor dendritic cells loaded with patient leukemic blasts preferentially induce CD4-positive leukemia-reactive donor lymphocytes. Acta Haematol; 2007;117(4):226-35
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic HLA-matched donor dendritic cells loaded with patient leukemic blasts preferentially induce CD4-positive leukemia-reactive donor lymphocytes.
  • BACKGROUND: The therapeutic value of donor lymphocyte infusions in patients who relapse with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT) is limited by a low efficacy and the risk of graft-versus-host disease.
  • We aimed at generating leukemia-reactive donor T cells for patients with AML.
  • One leukemia-reactive donor T cell line was expanded with a recently developed system.
  • CONCLUSIONS: Our results show the feasibility of the in vitro generation of leukemia-reactive donor lymphocytes, rendering this method a promising tool for post-HSCT immunotherapy.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. Dendritic Cells / transplantation. Histocompatibility Testing. Leukemia / therapy. Lymphocytes / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 S. Karger AG, Basel
  • (PMID = 17308369.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 82115-62-6 / Interferon-gamma
  •  go-up   go-down


29. Fuchs EJ, Huang XJ, Miller JS: HLA-haploidentical stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant; 2010 Jan;16(1 Suppl):S57-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical observations reveal a potential role for natural killer (NK) cell alloreactivity in reducing the risk of relapse of acute myeloid leukemia after HLA-haploidentical SCT.
  • NK cell infusions attempt to harness the graft-versus-leukemia effect without producing GVHD.

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3825-7 [12393440.001]
  • [Cites] Blood. 2003 Aug 1;102(3):814-9 [12689936.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1541-7 [12714500.001]
  • [Cites] Int J Hematol. 2004 Feb;79(2):178-84 [15005348.001]
  • [Cites] N Engl J Med. 1985 Sep 26;313(13):765-71 [3897863.001]
  • [Cites] Transplant Proc. 1987 Dec;19(6 Suppl 7):55-60 [3321647.001]
  • [Cites] N Engl J Med. 1989 Jan 26;320(4):197-204 [2643045.001]
  • [Cites] Hum Immunol. 1990 Oct;29(2):79-91 [2249952.001]
  • [Cites] Bone Marrow Transplant. 1991 Jun;7(6):443-52 [1873591.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1767-77 [9164184.001]
  • [Cites] N Engl J Med. 1998 Oct 22;339(17):1186-93 [9780338.001]
  • [Cites] Haematologica. 2004 Dec;89(12):1517-24 [15590404.001]
  • [Cites] Chin Med J (Engl). 2004 Dec;117(12):1778-85 [15603704.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1343-7 [15466923.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3051-7 [15632206.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3447-54 [15753458.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4370-6 [16131567.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3065-73 [16380454.001]
  • [Cites] Semin Immunol. 2006 Jun;18(3):145-50 [16740393.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):876-84 [16864058.001]
  • [Cites] Bone Marrow Transplant. 2006 Aug;38(4):291-7 [16883312.001]
  • [Cites] Immunity. 2006 Aug;25(2):331-42 [16901727.001]
  • [Cites] Immunol Rev. 2006 Dec;214:143-54 [17100882.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):690-7 [17228020.001]
  • [Cites] Blood. 2007 Jun 1;109(11):5058-61 [17317850.001]
  • [Cites] Lancet. 2007 Jun 9;369(9577):1947-54 [17560447.001]
  • [Cites] Blood. 2007 Jul 15;110(2):578-86 [17392508.001]
  • [Cites] Blood. 2007 Oct 15;110(8):3064-70 [17569820.001]
  • [Cites] Blood Cells Mol Dis. 2008 Jan-Feb;40(1):13-9 [17869547.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Apr;14(4):469-77 [18342790.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50 [18489989.001]
  • [Cites] J Clin Immunol. 2008 May;28(3):276-83 [18204965.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Nov;14(11):1279-87 [18940683.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1):109-17 [19135949.001]
  • [Cites] Bone Marrow Transplant. 2009 Jan;43(1):29-36 [18776927.001]
  • [Cites] Blood. 2009 Jan 15;113(3):726-32 [18945962.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Feb;15(2):257-65 [19167686.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 May;15(5):632-8 [19361756.001]
  • [Cites] Blood. 2002 Feb 1;99(3):806-14 [11806980.001]
  • (PMID = 19892024.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA121588-01A1; United States / NCI NIH HHS / CA / R21 CA121588; United States / NCI NIH HHS / CA / P01 CA015396; United States / NCI NIH HHS / CA / P01 CA015396-280019; United States / NCI NIH HHS / CA / CA015396-27A20019; United States / NCI NIH HHS / CA / CA121588-02; United States / NCI NIH HHS / CA / CA015396-280019; United States / NCI NIH HHS / CA / P01 CA015396-27A20019; United States / NCI NIH HHS / CA / R21 CA121588-02; United States / NCI NIH HHS / CA / CA121588-01A1
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  • [Number-of-references] 42
  • [Other-IDs] NLM/ NIHMS157348; NLM/ PMC2832726
  •  go-up   go-down


30. Lipton J, Joffe S, Ullrich NJ: CNS relapse of acute myelogenous leukemia masquerading as pseudotumor cerebri. Pediatr Neurol; 2008 Nov;39(5):355-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS relapse of acute myelogenous leukemia masquerading as pseudotumor cerebri.
  • An 18-year-old man in remission from acute myelogenous leukemia 3 years after a bone marrow transplant presented with signs of pseudotumor cerebri, including headache, visual changes, and papilledema.
  • He was diagnosed with an isolated central nervous system relapse of acute myeloid leukemia.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / diagnosis. Pseudotumor Cerebri / diagnosis. Pseudotumor Cerebri / etiology


31. Takahashi T, Tsukuda H, Kimura H, Yoshimoto M, Tsujisaki M: Extramedullary relapse of AML with t(9;11)(p22;q23) associated with clonal evolution from trisomy 8 into tetrasomy 8. Intern Med; 2010;49(5):447-51
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary relapse of AML with t(9;11)(p22;q23) associated with clonal evolution from trisomy 8 into tetrasomy 8.
  • This report describes a patient with extramedullary relapse of acute myeloid leukemia (AML) without involving bone marrow.
  • A 57-year-old man was diagnosed as having acute monoblastic leukemia with t(9;11)(p22;q23) and trisomy 8.
  • Aspiration from the forearm showed leukemic relapse, and fluorescence in situ hybridization (FISH) revealed that the majority of the cells had 11q23 anomaly and tetrasomy 8.
  • Bone marrow or meningeal relapse was not observed.
  • To our knowledge, this is the first case report of clonal evolution associated with the development of myeloid sarcoma as a relapse in AML.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 8 / genetics. Chromosomes, Human, Pair 9 / genetics. Leukemia, Myeloid, Acute / genetics. Sarcoma, Myeloid / diagnosis. Sarcoma, Myeloid / genetics. Trisomy / genetics

  • Genetic Alliance. consumer health - Chromosome 9, Trisomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20190481.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Giles F, Verstovsek S, Faderl S, Vey N, Karp J, Roboz G, Khan KD, Cooper M, Bilgrami SF, Ferrant A, Daenen S, Karsten V, Cahill A, Albitar M, Kantarjian H, O'Brien S, Feldman E: A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leuk Res; 2006 Dec;30(12):1591-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.
  • Cloretazine (VNP40101M) is a sulfonylhydrazine alkylating agent with significant anti-leukemia activity.
  • A multicenter phase II study of cloretazine was conducted in patients with first relapse of acute myeloid leukemia (AML) following an initial complete remission (CR) of less than 12 months.
  • [MeSH-major] Hydrazines / administration & dosage. Leukemia, Myeloid / drug therapy. Sulfonamides / administration & dosage
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Recurrence. Remission Induction. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16574225.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Letter; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydrazines; 0 / Sulfonamides; 14J2G0U3NQ / laromustine
  •  go-up   go-down


33. Giles F, Vey N, DeAngelo D, Seiter K, Stock W, Stuart R, Boskovic D, Pigneux A, Tallman M, Brandwein J, Kell J, Robak T, Staib P, Thomas X, Cahill A, Albitar M, O'Brien S: Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood; 2009 Nov 5;114(19):4027-33
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.
  • An international, randomized (2:1), double-blind, placebo-controlled study was conducted to compare complete remission (CR) rates and overall survival (OS) in patients with first relapse acute myeloid leukemia (AML) treated with laromustine and high-dose cytarabine (HDAC) versus HDAC/placebo.
  • [MeSH-major] Cytarabine / administration & dosage. Hydrazines / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Sulfonamides / administration & dosage

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2010 Jan 14;115(2):430 [20075171.001]
  • (PMID = 19710500.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00112554
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Hydrazines; 0 / Sulfonamides; 04079A1RDZ / Cytarabine; 14J2G0U3NQ / laromustine
  •  go-up   go-down


34. Hartwig M, Ocheni S, Asenova S, Wiedemann B, Zabelina T, Ayuk F, Kabisch H, Erttmann R, Kröger N, Zander AR, Bacher U: Second allogeneic stem cell transplantation in myeloid malignancies. Acta Haematol; 2009;122(4):185-92
MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second allogeneic stem cell transplantation in myeloid malignancies.
  • For patients with myeloid malignancies who relapse after allogeneic stem cell transplantation (allo-SCT), one salvage option is a second SCT.
  • We retrospectively analyzed outcomes of the second allo-SCT in 25 patients who received at least 2 allografts from related/unrelated donors due to relapse of acute myeloid leukemia, myelodysplastic syndrome or myelofibrosis after the first SCT.
  • A minority of the acute myeloid leukemia/myelodysplastic syndrome patients had reached complete hematological remission before the second SCT (6/25, 24%).
  • Complete remission was achieved in all 21 cases with available data after the second SCT, but relapse was seen in 11/25 patients (44%).
  • In 9 cases mortality was associated to relapse and in 8 cases to transplant-related causes (treatment-related mortality; 8/25, 32%).
  • In conclusion, a second SCT offers the chance of stable remission for some patients relapsing with a myeloid malignancy after a first allo-SCT, although high treatment-related mortality and relapse rates remain a problem.
  • [MeSH-major] Leukemia, Myeloid, Acute / surgery. Myelodysplastic Syndromes / surgery. Peripheral Blood Stem Cell Transplantation. Primary Myelofibrosis / surgery
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Transplantation. Child, Preschool. Female. Graft Survival. Graft vs Host Disease / etiology. Humans. Leukemia, Myelomonocytic, Juvenile / surgery. Male. Middle Aged. Polycythemia / complications. Recurrence. Reoperation. Retrospective Studies. Salvage Therapy. Transplantation Conditioning. Transplantation, Homologous. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19887774.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


35. Hanley KZ, Tadros TS, Briones AJ, Birdsong GG, Mosunjac MB: Hematologic malignancies of the female genital tract diagnosed on liquid-based Pap test: Cytomorphologic features and review of differential diagnoses. Diagn Cytopathol; 2009 Jan;37(1):61-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this review, we present three cases of hematologic gynecologic malignancies, two cases of primary NHL, and a case of acute myeloid leukemia with relapse as a pelvic mass, all of which were diagnosed on a liquid-based Pap test.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Uterine Cervical Neoplasms / diagnosis. Vaginal Neoplasms / diagnosis


36. Sumi M, Ichikawa N, Nasu K, Shimizu I, Ueki T, Ueno M, Kobayashi H: Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation. Int J Hematol; 2009 Dec;90(5):643-7
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation.
  • A 56-year-old woman with acute myelomonocytic leukemia underwent myeloablative allogeneic hematopoietic stem cell transplantation (allo-SCT) from a matched unrelated donor in her first complete remission (CR).
  • On day 58, she showed grade II acute GVHD, but this resolved spontaneously.
  • On day 140, she developed hematological relapse with 40.2% marrow infiltration of CD33-positive blasts.
  • Although the standard treatment for acute myeloid leukemia relapse after allo-SCT still remains to be established, GO may be a promising option.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myelomonocytic, Acute / drug therapy. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Acute Myelomonocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2002 Jul;30(1):23-8 [12105773.001]
  • [Cites] Leukemia. 2005 Feb;19(2):176-82 [15592433.001]
  • [Cites] Ann Hematol. 2001 Feb;80(2):119-20 [11261323.001]
  • [Cites] Blood. 1990 Feb 1;75(3):555-62 [2297567.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Aug;4(8):491-5 [17657254.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4371-83 [19029455.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1273-4 [17989711.001]
  • [Cites] Int J Hematol. 2009 May;89(4):460-9 [19360457.001]
  • [Cites] Leukemia. 2007 Jan;21(1):66-71 [17051246.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):495-503 [17952130.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1442-52 [16116598.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Leukemia. 2004 Feb;18(2):316-25 [14614514.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2247-8 [12960967.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4207-15 [12010827.001]
  • (PMID = 19904520.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 93NS566KF7 / gemtuzumab
  •  go-up   go-down


37. Valbuena JR, Admirand JH, Gualco G, Medeiros LJ: Myeloid sarcoma involving the breast. Arch Pathol Lab Med; 2005 Jan;129(1):32-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid sarcoma involving the breast.
  • CONTEXT: Myeloid sarcoma is a neoplasm of myeloid cells that can arise before, concurrent with, or following acute myeloid leukemia.
  • OBJECTIVE: To describe the clinicopathologic features of 6 patients with myeloid sarcoma involving the breast.
  • Routine hematoxylin-eosin-stained slides; naphthol AS-D chloroacetate stain; and immunohistochemical stains for myeloid, B-cell, and T-cell antigens were prepared.
  • Two patients presented with isolated tumors of the breast, with no history or subsequent development of acute myeloid leukemia.
  • In 3 patients, the breast tumors represented relapse of acute myeloid leukemia.
  • One patient who presented initially with myeloid sarcoma involving the breast, skin, and spleen was lost to follow-up.
  • CONCLUSIONS: Myeloid sarcoma involving the breast is uncommon.
  • In the literature, as in this study, these tumors most often represent relapse or the initial presentation of acute myeloid leukemia.
  • However, 2 of the cases we report presented with isolated masses, without a history or subsequent development of acute myeloid leukemia at last follow-up.
  • Immunohistochemical studies are extremely helpful for recognizing isolated myeloid sarcoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Sarcoma, Myeloid / diagnosis
  • [MeSH-minor] Acute Disease. Adult. Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Leukemia, Myeloid / diagnosis. Middle Aged. Recurrence. Skin Neoplasms / diagnosis. Splenic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15628906.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. Gale RE, Hills R, Kottaridis PD, Srirangan S, Wheatley K, Burnett AK, Linch DC: No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood; 2005 Nov 15;106(10):3658-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.
  • Fetal liver tyrosine kinase 3 (FLT3) internal tandem duplications (ITDs) are powerful adverse prognostic indicators for relapse in acute myeloid leukemia (AML) but the most efficacious therapy for FLT3/ITD(+) patients is currently unknown.
  • An FLT3/ITD was detected in 25% of patients and was an independent predictor for relapse (P < .001).
  • It remained prognostic for increased relapse in patients who received a transplant (odds ratio [OR] = 1.91; 95% confidence intervals [CIs] = 1.13-3.21; P = .02), with no evidence of a difference in effect between patients who received an autograft (OR = 2.39; CIs = 1.24-4.62) and patients who received an allograft (OR = 1.31; CIs = 0.56-3.06) (test for interaction, P = .3) or between patients who did or did not receive a transplant (P = .4).
  • [MeSH-major] Biomarkers, Tumor. Gene Duplication. Leukemia, Myeloid, Acute / therapy. Stem Cell Transplantation. fms-Like Tyrosine Kinase 3
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Great Britain. Humans. Leukemia, Promyelocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / metabolism. Leukemia, Promyelocytic, Acute / therapy. Male. Meta-Analysis as Topic. Middle Aged. Prognosis. Randomized Controlled Trials as Topic. Recurrence. Transplantation, Autologous. Transplantation, Homologous


39. Clozel T, Renneville A, Venot M, Gardin C, Kelaidi C, Leroux G, Eclache V, Preudhomme C, Fenaux P, Adès L: Slow relapse in acute myeloid leukemia with inv(16) or t(16;16). Haematologica; 2009 Oct;94(10):1466-8
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Slow relapse in acute myeloid leukemia with inv(16) or t(16;16).
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Oncogene Proteins, Fusion / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Feb 1;95(3):815-9 [10648391.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2521-8 [12468436.001]
  • [Cites] Blood. 2003 Jul 15;102(2):462-9 [12649129.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2746-55 [12842988.001]
  • [Cites] Leuk Res. 2009 Sep;33(9):1178-82 [19167754.001]
  • [Cites] Blood. 1998 Aug 1;92(3):784-9 [9680345.001]
  • [Cites] Leukemia. 2005 Mar;19(3):367-72 [15674426.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5705-17 [16110030.001]
  • [Cites] Leuk Res. 2006 Apr;30(4):389-95 [16243396.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2318-57 [14562125.001]
  • (PMID = 19608667.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / inv(16) fusion protein, human
  • [Other-IDs] NLM/ PMC2754969
  •  go-up   go-down


40. Kolitz JE: Very late relapse of acute myeloid leukemia. Leuk Lymphoma; 2007 Jan;48(1):3-4
Genetic Alliance. consumer health - Leukemia, Myeloid.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very late relapse of acute myeloid leukemia.
  • [MeSH-major] Leukemia, Myeloid / diagnosis
  • [MeSH-minor] Acute Disease. Humans. Recurrence. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Leuk Lymphoma. 2007 Jan;48(1):65-71 [17325849.001]
  • (PMID = 17325840.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  •  go-up   go-down


41. Stern M, Halter J, Buser A, Rovò A, Dirnhofer S, Häusermann P: Leukemia cutis preceding systemic relapse of acute myeloid leukemia. Int J Hematol; 2008 Mar;87(2):108-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia cutis preceding systemic relapse of acute myeloid leukemia.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Neoplasm Recurrence, Local. Skin Neoplasms / secondary

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301961.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Hingmire S, Narayanan P, Khadwal A, Maru D, Biswas G, Sastry PS, Parikh PM: Isolated cutaneous relapse of acute myeloid leukemia. J Assoc Physicians India; 2007 Feb;55:131
Genetic Alliance. consumer health - Leukemia, Myeloid.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated cutaneous relapse of acute myeloid leukemia.
  • [MeSH-major] Leukemia, Myeloid / diagnosis. Treatment Failure
  • [MeSH-minor] Acute Disease. Adult. Diagnosis, Differential. Erythema / diagnosis. Erythema / physiopathology. Humans. Male. Recurrence. Skin Diseases / diagnosis. Skin Diseases / physiopathology. Thorax / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17571743.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


43. Khan AA, Nazir S, Ahmed A: Relapse of acute myeloid leukemia presenting as acute otitis media. QJM; 2010 Jul;103(7):533-4
MedlinePlus Health Information. consumer health - Ear Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse of acute myeloid leukemia presenting as acute otitis media.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Otitis Media / etiology. Sarcoma, Myeloid / pathology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19793871.001).
  • [ISSN] 1460-2393
  • [Journal-full-title] QJM : monthly journal of the Association of Physicians
  • [ISO-abbreviation] QJM
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Seo HY, Kim SJ, Choi JW, Lee JB, Kang CH, Seo BK, Kim BS: Unusual relapse of acute myeloid leukemia: granulocytic sarcoma presenting as an acute paraplegia. Ann Hematol; 2006 Mar;85(3):196-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual relapse of acute myeloid leukemia: granulocytic sarcoma presenting as an acute paraplegia.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Neoplasms, Second Primary / pathology. Paraplegia / pathology. Sarcoma, Myeloid / pathology


45. Meloni G, Mancini M, Gianfelici V, Martelli MP, Foa R, Falini B: Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability. Haematologica; 2009 Feb;94(2):298-300
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Mutation. Nuclear Proteins / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):65-71 [17325849.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):254-66 [15659725.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3310-6 [16540685.001]
  • [Cites] Lancet Oncol. 2006 Apr;7(4):350-2 [16574551.001]
  • [Cites] Blood. 2006 Sep 15;108(6):1999-2005 [16720834.001]
  • [Cites] Blood. 2007 Feb 1;109(3):874-85 [17008539.001]
  • [Cites] Haematologica. 2008 Aug;93(8):1219-26 [18603563.001]
  • [Cites] Haematologica. 2007 Sep;92(9):1268-9 [17768124.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2776-84 [17957027.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3945-50 [18308931.001]
  • [Cites] Haematologica. 2008 May;93(5):775-9 [18367491.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • [ErratumIn] Haematologica. 2009 Aug;94(8):1182
  • (PMID = 19181793.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Mutant Proteins; 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin
  • [Other-IDs] NLM/ PMC2635402
  •  go-up   go-down


46. Lai YH, Chang CS, Liu YC, Liu TC: Postallogeneic hematopoietic stem cell transplantation relapse of acute myeloid leukemia presenting with salivary gland myelosarcoma. Ann Hematol; 2010 Jun;89(6):631-3
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postallogeneic hematopoietic stem cell transplantation relapse of acute myeloid leukemia presenting with salivary gland myelosarcoma.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy. Salivary Gland Neoplasms / secondary. Sarcoma, Myeloid


47. Ghadiany M, Attarian H, Hajifathali A, Khosravi A, Molanaee S: Relapse of acute myeloid leukemia as isolated bilateral testicular granulocytic sarcoma in an adult. Urol J; 2008;5(2):132-4; discussion 134-5
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse of acute myeloid leukemia as isolated bilateral testicular granulocytic sarcoma in an adult.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Sarcoma, Myeloid / pathology. Testicular Neoplasms / pathology


48. Lazarevic V, Wahlin A: Conditioning with fludarabine alone and allogeneic transplantation as a successful rescue therapy for persistent, severe iatrogenic aplasia after relapse of acute myeloid leukemia. Bone Marrow Transplant; 2007 Jan;39(1):53-4
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conditioning with fludarabine alone and allogeneic transplantation as a successful rescue therapy for persistent, severe iatrogenic aplasia after relapse of acute myeloid leukemia.
  • [MeSH-major] Anemia, Aplastic / chemically induced. Anemia, Aplastic / therapy. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid / complications. Transplantation Conditioning

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Aplastic Anemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17115065.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Myeloablative Agonists; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


49. Tempescul A, Ianotto JC, Eveillard JR, Guillerm G, Berthou C, Marion V, De Braekeleer M: High-dose melphalan followed by a second bone marrow transplantation in early relapse of acute myeloid leukemia after bone marrow transplantation in children. Ann Hematol; 2008 Jun;87(6):503-4
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose melphalan followed by a second bone marrow transplantation in early relapse of acute myeloid leukemia after bone marrow transplantation in children.
  • [MeSH-major] Bone Marrow Transplantation. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / surgery. Melphalan / therapeutic use






Advertisement